

This Patient Group Direction (PGD) must only be used by registered nurses who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

## Patient Group Direction

for the administration of







### Heparin Sodium to maintain patency of a Vascuport Central Venous Catheter (CVC)

by Registered Nurses for adult patients with a PORT (**Vascuport**) insitu

on all wards and outpatients departments across GHNHSFT

**PGD authorisation**

Version number: 02

Name	Job title and organisation	Signature	Date
PGD approval group Rachel Edwards Clare Roberts	NMP Lead GHNHSFT Senior Pharmacist Quality Assurance GHNHSFT	 	13/4/18 26-3-18
Senior pharmacist Martin Pratt	Chief Pharmacist GHNHSFT		3-4-18
Senior doctor/specialty Lead	Medical Director GHNHSFT		24/4/18
Senior representative of professional group using the PGD	MATRON - ONCOLOGY GHNHSFT		20.4.18
Person signing on behalf of the authorising body Steve Hams	Director of Quality and Chief Nurse GHNHSFT		13/04/18

## Training and competency

	<b>Requirements of registered nurses working under the PGD</b>
Qualifications and professional registration	Registered Nurses trained and competent in the care and management of PORT (Vascuport)
Initial training	Competent in the use of PGDs Trained in the administration of IV (Intravenous drugs) Trained in the administration of CVCs and PORTs
Competency assessment	PGD competency IV Drug administration Peripheral and Central Use of Totally Implantable Venous Access Device
Ongoing training and competency	As required and review at appraisal

## Clinical condition

Clinical condition or situation to which this PGD applies	Ongoing management of PORTs to maintain patency for blood sampling and the administration of blood products, drugs, fluids and other therapies that require intravenous access
Inclusion criteria	All adult patients with a Vascuport.
Exclusion criteria	NB. Note that patients with other types of Totally Implantable Venous Access Devices other than Vascuports may require alternative management. <ul style="list-style-type: none"> <li>• Children under 18 years</li> <li>• Allergy to heparin</li> <li>• Thrombocytopenia –Oncology/Haematology patients will need regular monitoring of platelet counts at the discretion of the medical clinician</li> <li>• Any potential complications i.e. Infection thrombosis, Catheter damage, Migration Pneumothorax and Bleeding refer to CVC Policy (Action Card no 22)</li> </ul>
Cautions (including any relevant action to be taken)	Patients sensitive to Low Molecular Weight Heparin
Arrangements for referral for medical advice	Seek medical advice
Action to be taken if patient excluded	Refer to CVC policy, seek expert advice and document on CVC Care plan
Action to be taken if patient declines treatment	Explain indications for maintaining patency and document

	reasons and actions.
--	----------------------

## **Patient information**

Written information to be given to patient or carer	
Follow-up advice to be given to patient or carer	Patient information can be obtained from Macmillan or through the PORT manufacturer. Seek Specialist advice if any problems noted.

## **Details of the medicine**

Name of medicine <i>Include ▼ for <u>black triangle medicines</u></i>	Heparin Sodium Solution 100 I.U./ml (international units)
Form of medicine	IV Flushing solution
Strength of medicine	100 I.U./ml
Legal category	POM
Indicate any <u>off-label use</u> (if relevant)	
Route/method of administration	IV
Dose and frequency	5ml (500 I.U.) every four to five weeks for maintenance or following any access
Quantity to be administered and/or supplied	5ml (500 I.U.)
Maximum or minimum treatment period	Lock the PORT with Heparin solution after every access and prior to removal of the non-coring Huber needle Gripper winged Infusion set
Adverse effects	Bleeding complications/hemorrhage. Rarely hypersensitivity NB. Heparin is likely to interfere with blood tests therefore heparin should be cleared from device before blood sample is taken
Records to be kept	<ul style="list-style-type: none"> <li>• Patient drug chart</li> <li>• CVC Care plan</li> </ul>

## **Key references**

1. BNF Section 2.8.1 Parenteral anticoagulants
2. EMC Summary of Product Characteristics
3. CVC Policy Insertion and Management (A0032.pdf)

